Elevated Serum Fibroblast Growth Factor 23 Levels As an Indicator of Lower Extremity Atherosclerotic Disease in Chinese Patients with Type 2 Diabetes Mellitus

Xingxing He,Xiang Hu,Xiaojing Ma,Hang Su,Lingwen Ying,Jiahui Peng,Xiaoping Pan,Yuqian Bao,Jian Zhou,Weiping Jia
DOI: https://doi.org/10.1186/s12933-017-0559-x
IF: 8.949
2017-01-01
Cardiovascular Diabetology
Abstract:Recently, basic and clinical studies have provided evidence supporting the relationship between circulating levels of fibroblast growth factor (FGF) 23 and the development of atherosclerosis. Given that diabetes is an established risk factor for lower extremity atherosclerotic disease (LEAD), the goal of the present study was to explore the relationship between serum FGF23 levels and LEAD, as well as the related factors, in Chinese patients with type 2 diabetes mellitus (T2DM).
What problem does this paper attempt to address?